Sign in

CIK 0001658551 · Non-accelerated filer<br>Smaller reporting company

Amylyx Pharmaceuticals, Inc.

Sign in to watch
Ticker
AMLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
EIN
464600503
Phone
617-682-0917
Business address
55 CAMBRIDGE PARKWAY, SUITE 6W, CAMBRIDGE, MA, 02142
  1. 4 Grant or award Co-Chief Executive Officer acquired 179,850 shares (grant or award)
  2. 4 Grant or award Chief Medical Officer acquired 96,910 shares (grant or award)
  3. 8-K Event Other events
  4. 8-K Event Exit or restructuring costs · Regulation FD disclosure · Other events
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 8-K Event Executive or director change
  8. SC 13G Stake Amended Statement of Ownership
  9. 8-K Event Regulation FD disclosure · Other events
  10. 4 Open-market sale Co-Chief Executive Officer sold 4,135 shares at $18.73 ($77,440)
  11. 4 Open-market sale Co-Chief Executive Officer sold 4,135 shares at $18.73 ($77,440)
  12. 4 Open-market sale Chief Financial Officer sold 1,792 shares at $18.73 ($33,560)
  13. 4 Open-market sale Chief Legal Officer sold 1,540 shares at $18.73 ($28,841)
  14. 4 Grant or award Chief Financial Officer acquired 40,000 shares (grant or award)
  15. 4 Grant or award Co-Chief Executive Officer acquired 126,667 shares (grant or award)
  16. 4 Grant or award Co-Chief Executive Officer acquired 126,667 shares (grant or award)
  17. 4 Grant or award Chief Legal Officer acquired 36,667 shares (grant or award)
  18. 4 Open-market sale Chief Legal Officer sold 2,838 shares at $18.76 ($53,231)
  19. S-8 Other Securities Offered to Employees in Benefit Plans
  20. 10-K Report Annual Report

Page 12 of 23 · 446 filings